Drawing for HUMABS

USPTO serial 87180081

HUMABS

Reviewed by CopyMark Law Group

Reg. 5477354Status 710
Filing date
Status date
Registration date
May 22, 2018
Examiner
SCHWAB, MATTHEW DAVID
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with HUMABS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Tamar Niv Bessinger

Tamar Niv Bessinger Fross Zelnick Lehrman & Zissu, P.C.151 West 42nd Street, 17th floorNew York, NY 10036United States

Goods and services

ClassDescriptionStatusFirst use
001Chemical products for industrial or scientific purposes, namely, chemical preparations for scientific purposes, chemical preparations for industrial purposes; reagents for laboratory purposesSECTION 8 - CANCELLED—
005Pharmaceutical and veterinary products for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, viral, bacterial or protozoological infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; organic compounds, biomolecules or biological macromolecules in the nature of pharmaceutical preparations for pharmaceutical purposes, namely for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, viral, bacterial or protozoological infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; organic compounds, biomolecules or biological macromolecules in the nature of pharmaceutical preparations for the treatment of viral, bacterial or protozoological infectionsSECTION 8 - CANCELLED—
042Scientific and technology services, namely, scientific research, analysis and testing and research and design in the field of chemicals and biologicals; laboratory services, namely, laboratory services in the field of biological macromolecules, drug discovery, preclinical and clinical development of therapeutic products; research services, namely, scientific research, research in the field of biological macromolecules; research services in the field of employing biological macromolecules; research services in the field of optimizing biological macromolecules; services for testing pharmaceutical products in terms of their biological or drug behavior; services for carrying out pre-clinical or clinical studies, namely, conducting studies for preclinical and clinical testing of biological products; services for testing biological productsSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 6, 2024C8..CANCELLED SEC. 8 (6-YR)—
Apr 1, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 1, 2024EWORTEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED—
Apr 1, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 1, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Apr 1, 2024CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Apr 1, 2024COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
May 22, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
May 22, 2018R.SRREGISTERED-SUPPLEMENTAL REGISTERYour mark is registered on the Supplemental Register, which is available for marks that are not yet distinctive enough for the Principal Register but can still identify a source. Protection is more limited than Principal Register registration but can later support a Principal Register application.
Apr 17, 2018PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Apr 11, 2018CNTAAPPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER—
Mar 7, 2018TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 7, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 7, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 7, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 7, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 7, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 7, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 2, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 2, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 1, 2017ALIEASSIGNED TO LIE—
Jun 28, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 30, 2016GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 30, 2016GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 30, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 29, 2016DOCKASSIGNED TO EXAMINER—
Sep 27, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 26, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance